Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGER trial: TIP versus TI-CE as first salvage therapy for relapsed or refractory germ cell tumors
NL-OMON59883Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel, ifosfamide, cisplatin, carboplatin and etoposide in germ cell tumor (GCT) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival. Started Nov 2016; status: active, not recruiting.
02
Drugs
paclitaxelifosfamidecisplatincarboplatinetoposide
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NL-OMON59883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59883.